Brief: Enlivex Announces Interim Data From Phase I/II trial Evaluating Allocetra In End-Stage Knee Osteoarthritis
17/06/2024 13:05
June 17 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES POSITIVE INTERIM DATA READOUT FROM A
PHASE
I/II TRIAL EVALUATING ALLOCETRA IN END-STAGE KNEE OSTEOARTHRITIS
Source text for Eikon: ID:nGNXbYq5jR
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment